CN1101673C - 防治口腔病的口洁液及制备方法 - Google Patents
防治口腔病的口洁液及制备方法 Download PDFInfo
- Publication number
- CN1101673C CN1101673C CN97116074A CN97116074A CN1101673C CN 1101673 C CN1101673 C CN 1101673C CN 97116074 A CN97116074 A CN 97116074A CN 97116074 A CN97116074 A CN 97116074A CN 1101673 C CN1101673 C CN 1101673C
- Authority
- CN
- China
- Prior art keywords
- oral
- present
- group
- preparation
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000214 mouth Anatomy 0.000 title claims abstract description 13
- 238000004140 cleaning Methods 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 201000010099 disease Diseases 0.000 title description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
- 239000000843 powder Substances 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims abstract description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 6
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims abstract 5
- 241001593750 Turcica Species 0.000 claims description 7
- 230000007170 pathology Effects 0.000 claims description 7
- 229940109275 cyclamate Drugs 0.000 claims description 5
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- -1 adding correctives Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract 2
- 244000246386 Mentha pulegium Species 0.000 abstract 1
- 235000016257 Mentha pulegium Nutrition 0.000 abstract 1
- 235000004357 Mentha x piperita Nutrition 0.000 abstract 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 238000011049 filling Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 235000001050 hortel pimenta Nutrition 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 229940013618 stevioside Drugs 0.000 abstract 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 abstract 1
- 235000019202 steviosides Nutrition 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 239000003814 drug Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010018691 Granuloma Diseases 0.000 description 6
- 210000003371 toe Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010006326 Breath odour Diseases 0.000 description 4
- 208000032139 Halitosis Diseases 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- KJHJAABRDASKAF-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione Chemical compound OC1=NC(O)=C2N=CNC2=N1.O=C1NC(=O)NC2=C1NC=N2 KJHJAABRDASKAF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000009019 Pericoronitis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种防治口腔病的口洁液及其制备方法,它是以没食子干粉为主要药料配以甜密素,簿菏香精,苯甲酸钠等药,加水浸泡,煎煮,过滤,合并滤液,滤液依次加娇味剂,香精及防腐剂适量,搅拌溶解,加水稀释至足量,分装即得。本发明药源丰富,加工操作简便,成本低,疗效高,预防好,疗程短,无毒副作用,使用方便等优点。
Description
本发明涉及一种防治口腔病的口洁液及其制备方法,它主要用于防治扁桃体炎、牙周病、齿根炎、牙冠周炎、口腔粘膜病以及咽喉部疼痛、口臭等症。
在我国口腔病发病率已达90%以上,口腔有无疾病直接影响到一个人的工作、生活和学习,因此提倡口腔保健工作是十分重要的。目前使用的抗菌素类药、磺胺类药等均有不同程度的副作用,不能长期使用。“大佛喉露”(喷雾剂,香港美加康医药保健公司产品),是目前疗效较突出的治疗口腔疾病的药物。但是其价格昂贵,疗效不能令人满意。
本发明的目的在于解决上述问题,提供一种疗效高、预防好、疗程短、无毒副作用、药源丰富、价格低廉、使用方便的防治口腔病的口洁液及其制备方法。
本发明的目的可以通过以下措施来实现:
一种防治口腔病的口洁液,每100ml本发明中各组份的含量为:
没食子干粉 0.1~10g
甜蜜素 0.1~1g
薄荷香精 0.0025~0.25ml
苯甲酸钠 0.001~0.1ml
本发明的制备方法:取没食子药材粉粹过4号筛,加水浸泡1小时煎煮提取3次,每次0.5小时过虑合并滤液,滤液依次加娇味剂,香精及防腐剂适量,搅拌溶解,加水稀释至足量,分装即得。
本发明的使用方法:每次嗽口3ml、每日3~5次。
本发明具有如下优点:疗效高,预防好,疗程短,无毒副作用,加工操作简便,制造成本很低,药源丰富,使用方便。
下面结合实施方案对本发明和大佛喉露进行了药效研究,对其作了比较,实验结果如下:
1、消炎作用
(1)对小鼠足趾角叉菜胶致肿的影响
取昆明种小鼠50只,随机分为NS对照组,大佛喉露阳性对照组及三个不同剂量的本发明组。每日两次,连续灌胃给药9天,于末次给药后1h,右足趾SC2%角叉菜胶0.06ml,致炎后1h,2h,3h,6h用千分尺测量足趾厚度,以致炎前后足趾厚度为肿胀度进行组间均数t检验。结果,本发明ig给药5.0,10.0,20.0ml/kg,bid×9d,对角叉菜胶致小鼠足趾肿胀均有明显抑制作用,其效应优于大佛喉露,提示该药有较强的消肿作用(表1)。
表1.本发明对小鼠足趾角叉菜胶致肿的影响(x±S)
肿胀度(mm)组 别 n 剂量
(ml/kg.bid×9d) 1h 8h 24hNS水对照组 10 20.0 1.441±0.163 2.319±0.310 2.004±0.512本发明组 10 5.0 1.053±0.366*** 1.948±0.349** 1.473±0.401**
10 10.0 1.063±0.294*** 1.917±0.467** 1.546±0.437**
10 20.0 0.889±0.325**** 1.731±0.564**** 1.258±0.493***大佛喉露组 10 10.0 1.123±0.288*** 2.071±0.334* 1.480±0.382**注:与生理盐水对照组比较*p>0.05,**p<0.05,***p<0.01,****p<0.001
(2)对小白鼠腹腔毛细血管通透性增加的影响
取昆明种小鼠50只,体重19.8±1.2g,雌雄各半,随机分NS对照组,大佛喉露阳性对照组及三个不同剂量的本发明组,每组10只动物,每日两次,连续ig给药5天,末次给药后30min,小鼠尾静脉注射伊文斯蓝(2g/10ml)0.15ml/只,同时ip0.6%醋酸0.2ml/只,20min后处死小鼠,剪开腹腔,用5ml蒸留水冲洗腹腔数次,收集洗涤液5~6ml,2500rpm离心5min,用721一型分光光度计590nm处测定吸收度(OD值),结果见表2。
表2.本发明对乙酸所致小鼠腹腔毛细血管通透性增加的影响(x±S)组 别 n 剂量(ml/kg.bid×5d) 腹腔洗出液光密度值(OD值)NS对照组 9 20.0 1.033±0.302本发明组 9 5.0 0.884±0.357*
9 10.0 0.794±0.214*
9 15.0 0.609±0.296**大佛喉露组 9 10.0 0.888±0.376*
注:与蒸留水对照组比较*p>0.05,**p<0.05。
结果,本发明5.0,10.0,15.0ml/kg,bid×5d,对小鼠乙酸所致腹腔毛细血管通透性增加有抑制作用,其中大剂量组作用明显,提示该药对致炎剂所致毛细血管通透性增加有抑制作用,其效应优于大佛喉露。
(3)对大白鼠棉球肉芽肿的影响
取大鼠38只,腹腔注射戊巴比妥钠3mg/100g麻醉。在各鼠的左右腋下用碘洒消毒,洒精脱碘后,各切开1cm长小口,将20±0.2mg的灭菌棉球植入皮下。术后将动物随机分成5组,分别ig本发明(10.0,20.0,30.0ml/kg),大佛喉露(10ml/kg)及生理盐水(20ml/kg)。手术当天开始给药,一天两次,连续7天,第8天先称体重,而后处死动物,剥离并取出棉球肉芽肿组织,于60℃烘箱内干燥12h后称重,减去原棉球重,即为肉芽肿净重,结果见表3。
表3.本发明对大鼠棉球肉芽肿形成的影响组 别 n 剂量(ml/kg.bid×8d) 肉芽肿干重(mg)本发明组 6 10.0 66.07±3.33***
7 20.0 65.12±12.90**
9 30.0 67.73±2.64***大佛喉露组 8 10.0 69.61±12.14**NS对照组 8 20.0 88.52±10.61
注:与生理盐水对照组比较**p<0.01,***p<0.001。
结果表明,本发明各组均能明显的抑制大鼠棉球肉芽组织增生,提示该药能明显仰制慢性炎症反应。
2、镇痛作用
(1)对乙酸所致小鼠扭体反应的影响
取昆明种小鼠60只,随机分NS对照组,大佛喉露阳性对照组及三个不同剂量的本发明组,按下述剂量,每日两次,连续ig给药4天,末次给药后1h每鼠1p5%冰醋酸0.2ml/只,观察每只小鼠15mim内因疼痛引起的扭体次数,以扭体次数进行组间均数t检验,结果见表4。
表4.本发明对小鼠乙酸致痛扭体反应的影响(x±S)组 别 n 剂量(g/kg×bid) 扭体次数(x±S)NS对照组 10 20ml 24.00±8.21本发明组 10 0.1 14.45±7.59*△
10 0.2 9.80±5.79***△
10 0.3 12.50±8.75**△大佛喉露组 10 10.ml 10.30±6.58***
注:与生理盐水对照组比较*p<0.05,**p<0.01,***p<0.001,与大佛喉露组比较△p>0.05。
结果表明,本发明(0.1,0.2,0.4g/kg bid×4d)对小鼠乙酸致痛扭体反应有明显抑制作用,其中0.2g/kg×bid组效果特别明显。该受试物不同剂量所出现的效应与大佛喉露阳性对照组的效应相比在统计学上没有差异。说明这两种药物的镇痛作用相仿。
3、对干酵母所致大白鼠发热的清热作用
取Wistar大鼠35只,随机分5组,每组7只。各组动物分别ig本发明(10.0,20.0,30.0ml/kg),大佛喉露(10ml/kg),生理盐水(20.0ml/kg),每日两次,连续3天,末次给药前先测基础体温,给药后1h各鼠立即于背部皮下注入20g/dl酵母混悬液1ml/100g,此后0.5,1,2,4,6,8,10,12h各测动物体温一次,以不同时间所测肛温与基础肛温之差值,为体温变化的指标,各组进行统计学处理,结果见附图。
附图为本发明对酵母所致大鼠体温变化的影响
。一。对照,。——。小剂量组,△-△中剂量组,□-□大剂量组,×-×阳性对照组
如附图所示,不同剂量的本发明对酵母所致大鼠体温升高有明显的抑制作用并有明显的剂量效应关系。提示该药具有很强的解热作用。
4、对二硝基氯苯诱导的迟发型超敏反应的影响
取小鼠70只,随机分为三个不同剂量的本发明组及大佛喉露对照组,每日两次,连续11天。给药后5天,每组腹部剪毛(2×2cm2),将1%二硝基氯苯溶液50ul均匀涂抹于剪毛处皮肤致敏。致敏后第5天,将1%二硝基氯苯溶液50ul均匀涂抹于小鼠右耳两面进行抗原攻击,攻击后24h,处死小鼠,剪下左右耳壳,用打空器取下直径8mm的耳片,称重,以左右耳片重量之差为肿胀程度,分别以每10g小鼠的肝(mg)胸腺重量(mg)作为肝指数和胸腺指数,进行组间均数t检验,结果见表5。
表5.本发明对二硝基氯苯诱导的迟发型超敏反应的影响(x±S)组 别 n 剂量(ml/kg.bid) 肿胀度 胸腺指数 肝指数NS水对照组 13 20 36.5±9.9 44.8±11.4模型组 12 20 3.29±1.23 29.8±9.0 55.2±10.5本发明组 12 10 2.71±0.92 27.0±11.9 49.2±14.8
12 20 3.13±1.51 26.0±6.6 49.2±18.4
10 30 2.30±1.31 22.9±9.4 59.5±12.9大佛喉露组 10 20 2.45±1.10 23.1±9.6 49.8±10.0
结果表明,本发明对二硝基氯苯所致迟发型超敏反应有抑制趋势,但没有统计学意义。
5、清除活性氧功能
(1)、对超氧阴离子的清除作用——采用黄嘌呤—黄嘌呤氧化酶—鲁米诺化学发光体系; IC50=0.417ug(本发明)
IC50=26.67ug(大佛喉露)
(2)、对羟自由基的清除作用——采用CuSO4—ViTc—酵母—H2O2化学法光体系; IC50=280ug(本发明)
IC50=868ug(大佛喉露)
(3)、对过氧化氢的分解作用——采用血红蛋白(Hb)—鲁米诺—ddH2O—OH-化学发光体系; IC50=96ug(本发明)
IC50=230ug(大佛喉露)
上述结果显示,本发明具有很强的清除各类活性氧的作用,其功效大于大佛喉露。
注:IC50系抑制发光50%时的药物浓度。
动物急性毒性试验:
为了确定本发明的毒性大小,本试验测定了本发明的LD50。
试验目的:观察本发明一次灌胃给予动物后,所产生的毒性反应的死亡情况。
受试药物:本发明以水提煎煮法制备。
受试动物:昆明种小鼠,体重20.3±1.2g雌雄各半。新疆维吾尔自治区医学实验动物中心提供。合格证书,新疆医动学94,16-001号。
方法与结果:
1、预试验
用寇氏法找出本发明的最小全致死量(LD100)及最大全不死量(LD0)。结果LD0=1.5g/kg×b.i.d,LD100=4.5g/kg×bid.
2、正式试验
取小鼠50只,随机分5组,每组5只,按下表所示浓度及剂量连续两次灌胃给药,每次间隔2h,给药后连续观察7天,结果如下:剂量(mg/kg) 4620 5760 7200 9018 11220死亡数(r/n) 1/10 1/10 3/10 8/10 10/10用CASIO FX-189P计数器,程序按BIiss法计算LD50。表1.LD50 BIiss法列表D P Ye Y n W A B Yr Yr-Y11220 1.00 7.24 6.80 10 0.180 12.666 5.441 6.63 -0.179018 0.80 5.84 5.93 10 0.471 3.758 2.833 5.76 -0.177200 0.30 4.48 5.00 10 0.636 2.507 3.740 4.85 -0.155760 0.10 3.72 4.08 10 0.471 3.758 3.408 3.96 -0.124620 0.10 3.72 3.17 10 0.180 12.666 2.745 3.08 -0.09
1Yr-Y1<0.2,回归结果满意,计算结果为LD50=7465.91mg/kg,S50=2.48×10-2,95%可信限(FL)=6673.05-8352.97mg/kg。
结论:本发明的小鼠经口LD50 7.4g/kg。成人每次3ml,每日3次,共9ml(相当于生药270mg)。该药的LD50为成人用量的1644倍。因此,可以认为本发明安全无毒。
本发明的临床观察结果如下:病名 总人数 治愈 好转 无效 毒副作用牙周炎 156 141 15 0 无口腔溃疡 158 154 4 0 无牙龈松弛 146 133 13 0 无咽喉炎 151 140 11 0 无口臭、烟臭 142 140 2 0 无
结果表明,该口洁液对牙周炎、口腔溃疡、口臭、牙龈松弛、咽喉炎、口臭、烟臭等多种口腔疾病具有良好的疗效;
实施例1:
没食子干粉 21g
甜蜜素 2.0g
薄菏香精 3.6ml
苯甲酸钠 0.22g
实施例2:
没食子干粉 42g
甜蜜素 3.0g
薄菏香精 7.8ml
苯甲酸钠 0.25g
实施例3:
没食子干粉 5g
甜蜜素 1.3g
薄菏香精 3.1ml
苯甲酸钠 0.15g
Claims (2)
1.一种防治口腔病的口洁液,其特征在于:每100ml本发明中各组份的含量为:
没食子干粉 0.1~10g
甜蜜素 0.1~1g
薄荷香精 0.0025~0.25ml
苯甲酸钠 0.001~0.1ml
2.一种防治口腔病的口洁液的制备方法,其特征在于取没食子药材粉碎过4号筛,加水浸泡1小时煎煮提取3次,每次0.5小时过滤合并滤液,滤液依次加娇味剂,香精及防腐剂适量,搅拌溶解,加水稀释至足量,分装即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97116074A CN1101673C (zh) | 1997-08-21 | 1997-08-21 | 防治口腔病的口洁液及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97116074A CN1101673C (zh) | 1997-08-21 | 1997-08-21 | 防治口腔病的口洁液及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1209314A CN1209314A (zh) | 1999-03-03 |
CN1101673C true CN1101673C (zh) | 2003-02-19 |
Family
ID=5173648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97116074A Expired - Fee Related CN1101673C (zh) | 1997-08-21 | 1997-08-21 | 防治口腔病的口洁液及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1101673C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA011286B1 (ru) * | 2007-08-29 | 2009-02-27 | Общество С Ограниченной Ответственностью "Вдс" | Таблетка для профилактики и лечения заболеваний зубов и пародонта |
CN108926636A (zh) * | 2018-10-19 | 2018-12-04 | 新疆奇沐医药研究院(有限公司) | 一种植物抑菌剂及其制备方法 |
-
1997
- 1997-08-21 CN CN97116074A patent/CN1101673C/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
《中国医院药学杂志》8(4) 1988-01-01 梁兴才等,"口腔溃疡膜的制备" * |
《新疆中医药》1995,(4) 1995-01-01 周强中等,"维吾尔医方吹喉散";《药学通报》23(10) 1998-01-01 胡琴等,"全中药牙髓快速失活剂的配制及疗效观察";《中国医院药学杂志》8(4) 1988-01-01 梁兴才等,"口腔溃疡膜的制备" * |
《新疆中医药》1995,(4) 1995-01-01 周强中等,"维吾尔医方吹喉散" * |
《药学通报》23(10) 1998-01-01 胡琴等,"全中药牙髓快速失活剂的配制及疗效观察" * |
Also Published As
Publication number | Publication date |
---|---|
CN1209314A (zh) | 1999-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1302793C (zh) | 烧伤万应膏及制备工艺 | |
CN1927160A (zh) | 漱口液及制备方法 | |
CN1899505A (zh) | 一种清热泻火的药物组合物 | |
CN106619969A (zh) | 用于治疗鼻炎的鼻腔冲洗液 | |
CN101053568A (zh) | 一种复方磺胺间甲氧嘧啶钠注射液的配方及制作工艺 | |
CN1101673C (zh) | 防治口腔病的口洁液及制备方法 | |
CN107951764A (zh) | 一种具有预防口腔溃疡和修复口腔黏膜功效的中药牙膏 | |
CN1284585C (zh) | 治疗急慢性咽喉炎、复发性口腔溃疡的药物及制备方法 | |
CN1565551A (zh) | 治疗口腔疾病的中药及其制备方法 | |
CN1259939C (zh) | 一种治疗口腔疾病的中药制剂及制备方法 | |
CN1293913C (zh) | 一种治疗急慢性咽炎的中药袋泡茶剂及其生产方法 | |
CN1167455C (zh) | 治疗痤疮的药物及其制备方法 | |
CN1238032C (zh) | 治疗粉刺的酊剂及其制备方法 | |
CN1293897C (zh) | 一种烧烫伤散 | |
CN1251753C (zh) | 一种治疗乳腺增生病的外用药组合物及其制备方法 | |
CN1772098A (zh) | 一种治疗慢性咽炎及痰热症的中药组合物及其制备工艺 | |
CN1686414A (zh) | 祛伤消肿酊及其制备方法 | |
CN1294937C (zh) | 治疗腋臭的中药药剂 | |
CN1224399C (zh) | 一种治疗疣病的药物组合物 | |
CN1265810C (zh) | 一种治疗乳腺增生病的药物组合物及其制备方法 | |
CN1275591C (zh) | 一种治疗心血管疾病的中药缓释剂及其制备方法 | |
CN1552428A (zh) | 一种外用抗真菌的中药组合物 | |
CN1261121C (zh) | 一种治疗便秘、口臭、牙龈肿痛的药物 | |
CN1281255C (zh) | 治疗皮肤病或糖尿病患者下肢溃疡的药物及其制备方法 | |
CN1562210A (zh) | 地榆口腔崩解片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |